Home ➤ Life Science ➤ Therapeutics ➤ Cystic-Fibrosis Therapeutics Market
Cystic-Fibrosis Therapeutics Market
Published date: July 2024 • Formats:
[email protected] +1 718 874 1545
Request Sample Schedule a Call

Table of Contents

Cystic-Fibrosis Therapeutics Market By Drug Class(Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Pancreatic Enzyme Supplement, Bronchodilators, Other Drug Classes) By Route of Administration(Oral, Parenteral) By Distribution Channel(Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: July 2024
  • Report ID: 78573
  • Number of Pages: 245
  • Format:
Fact Checked
Cystic-Fibrosis Therapeutics Market https://market.us/report/cystic-fibrosis-therapeutics-market/
Cite this Research
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global Cystic Fibrosis Therapeutics Overview
      • 2.1. Cystic Fibrosis Therapeutics Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.2. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 3.2. Global Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 3.3. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 3.3.1. Global Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 3.3.3. CFTR modulators
        • 3.3.4. Mucolytics
        • 3.3.5. Pancreatic enzyme supplements
        • 3.3.6. Bronchodilators
      • 3.4. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 3.4.1. Global Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 3.4.3. Oral drugs
        • 3.4.4. Inhaled drugs
    • 4. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 4.2. North America Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 4.3. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 4.3.1. North America Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 4.3.3. CFTR modulators
        • 4.3.4. Mucolytics
        • 4.3.5. Pancreatic enzyme supplements
        • 4.3.6. Bronchodilators
      • 4.4. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 4.4.1. North America Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 4.4.3. Oral drugs
        • 4.4.4. Inhaled drugs
      • 4.5. North America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.5.1. North America Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.5.2.1. U.S.
          • 4.5.2.2. Canada
          • 4.5.2.3. Mexico
    • 5. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Europe Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 5.2. Europe Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 5.3. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 5.3.1. Europe Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 5.3.3. CFTR modulators
        • 5.3.4. Mucolytics
        • 5.3.5. Pancreatic enzyme supplements
        • 5.3.6. Bronchodilators
      • 5.4. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 5.4.1. Europe Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 5.4.3. Oral drugs
        • 5.4.4. Inhaled drugs
      • 5.5. Europe Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.5.1. Europe Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.5.2.1. U.K.
          • 5.5.2.2. Germany
          • 5.5.2.3. France
          • 5.5.2.4. Spain
          • 5.5.2.5. Italy
          • 5.5.2.6. Russia
          • 5.5.2.7. Rest of Europe
    • 6. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 6.2. Asia-Pacific Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 6.3. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 6.3.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 6.3.3. CFTR modulators
        • 6.3.4. Mucolytics
        • 6.3.5. Pancreatic enzyme supplements
        • 6.3.6. Bronchodilators
      • 6.4. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 6.4.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 6.4.3. Oral drugs
        • 6.4.4. Inhaled drugs
      • 6.5. Asia-Pacific Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.5.1. Asia-Pacific Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.5.2.1. China
          • 6.5.2.2. Japan
          • 6.5.2.3. South Korea
          • 6.5.2.4. India
          • 6.5.2.5. Rest of Asia-Pacific
    • 7. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. South America Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 7.2. South America Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 7.3. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 7.3.1. South America Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 7.3.3. CFTR modulators
        • 7.3.4. Mucolytics
        • 7.3.5. Pancreatic enzyme supplements
        • 7.3.6. Bronchodilators
      • 7.4. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 7.4.1. South America Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 7.4.3. Oral drugs
        • 7.4.4. Inhaled drugs
      • 7.5. South America Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.5.1. South America Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.5.2.1. Brazil
          • 7.5.2.2. Argentina
          • 7.5.2.3. Rest of South America
    • 8. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, 2016-2021
      • 8.2. Middle East and Africa Cystic Fibrosis Therapeutics Opportunity and Forecast, 2023-2032
      • 8.3. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
        • 8.3.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Drug Class: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
        • 8.3.3. CFTR modulators
        • 8.3.4. Mucolytics
        • 8.3.5. Pancreatic enzyme supplements
        • 8.3.6. Bronchodilators
      • 8.4. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
        • 8.4.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Route of Administration: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
        • 8.4.3. Oral drugs
        • 8.4.4. Inhaled drugs
      • 8.5. Middle East and Africa Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.5.1. Middle East and Africa Cystic Fibrosis Therapeutics Analysis by Country : Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.5.2.1. GCC
          • 8.5.2.2. Israel
          • 8.5.2.3. South Africa
          • 8.5.2.4. Rest of MEA
    • 9. Global Cystic Fibrosis Therapeutics Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 9.1. Global Cystic Fibrosis Therapeutics Analysis by Region : Introduction
      • 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 9.2.1. North America
        • 9.2.2. Europe
        • 9.2.3. Asia-Pacific
        • 9.2.4. South America
        • 9.2.5. Middle East and Africa
    • 10. Global Cystic Fibrosis Therapeutics Competitive Landscape, Market Share Analysis, and Company Profiles
      • 10.1. Market Share Analysis
      • 10.2. Company Profiles
      • 10.3. Hoffmann-La Roche Ltd.
        • 10.3.1. Company Overview
        • 10.3.2. Financial Highlights
        • 10.3.3. Product Portfolio
        • 10.3.4. SWOT Analysis
        • 10.3.5. Key Strategies and Developments
      • 10.4. Gilead
        • 10.4.1. Company Overview
        • 10.4.2. Financial Highlights
        • 10.4.3. Product Portfolio
        • 10.4.4. SWOT Analysis
        • 10.4.5. Key Strategies and Developments
      • 10.5. Teva Pharmaceutical Industries Ltd.
        • 10.5.1. Company Overview
        • 10.5.2. Financial Highlights
        • 10.5.3. Product Portfolio
        • 10.5.4. SWOT Analysis
        • 10.5.5. Key Strategies and Developments
      • 10.6. Novartis AG
        • 10.6.1. Company Overview
        • 10.6.2. Financial Highlights
        • 10.6.3. Product Portfolio
        • 10.6.4. SWOT Analysis
        • 10.6.5. Key Strategies and Developments
      • 10.7. Vertex Pharmaceuticals Inc.
        • 10.7.1. Company Overview
        • 10.7.2. Financial Highlights
        • 10.7.3. Product Portfolio
        • 10.7.4. SWOT Analysis
        • 10.7.5. Key Strategies and Developments
      • 10.8. Alcresta Therapeutics
        • 10.8.1. Company Overview
        • 10.8.2. Financial Highlights
        • 10.8.3. Product Portfolio
        • 10.8.4. SWOT Analysis
        • 10.8.5. Key Strategies and Developments
      • 10.9. Merck & Co. Inc.
        • 10.9.1. Company Overview
        • 10.9.2. Financial Highlights
        • 10.9.3. Product Portfolio
        • 10.9.4. SWOT Analysis
        • 10.9.5. Key Strategies and Developments
      • 10.10. AIT (Advanced Inhalation Therapies)
        • 10.10.1. Company Overview
        • 10.10.2. Financial Highlights
        • 10.10.3. Product Portfolio
        • 10.10.4. SWOT Analysis
        • 10.10.5. Key Strategies and Developments
      • 10.11. Other Key Players
        • 10.11.1. Company Overview
        • 10.11.2. Financial Highlights
        • 10.11.3. Product Portfolio
        • 10.11.4. SWOT Analysis
        • 10.11.5. Key Strategies and Developments
    • 11. Assumptions and Acronyms
    • 12. Research Methodology
    • 13. Contact

     

    • List of Figures
      • Figure 1: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Class in 2022
      • Figure 2: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 3: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 4: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 5: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Region in 2022
      • Figure 6: Global Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Region, 2016-2032
      • Figure 7: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 8: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Figure 9: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 10: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 11: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Figure 12: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 13: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 14: Global Cystic Fibrosis Therapeutics Market Share Comparison by Region (2016-2032)
      • Figure 15: Global Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 16: Global Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 17: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 18: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 19: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 20: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 21: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 22: North America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 23: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 24: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 25: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 26: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 27: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 28: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 29: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 30: North America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 31: North America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 32: North America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 33: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 34: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 35: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 36: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 37: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 38: Europe Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 39: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 40: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 41: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 42: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 43: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 44: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 45: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 46: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 47: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 48: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 49: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 50: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 51: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 52: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 53: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 54: Asia-Pacific Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 55: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 56: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 57: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 58: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 59: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 60: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 61: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 62: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 63: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 64: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 65: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 66: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 67: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 68: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 69: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 70: South America Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 71: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 72: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 73: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 74: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 75: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 76: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 77: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 78: South America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 79: South America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 80: South America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Figure 81: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Drug Classin 2022
      • Figure 82: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Drug Class, 2016-2032
      • Figure 83: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Route of Administrationin 2022
      • Figure 84: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2016-2032
      • Figure 85: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 86: Middle East and Africa Cystic Fibrosis Therapeutics Market Attractiveness Analysis by Country, 2016-2032
      • Figure 87: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Figure 88: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 89: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Figure 90: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Figure 91: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 92: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Figure 93: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Figure 94: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Figure 95: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Figure 96: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)

       

    • List of Tables
      • Table 1: Global Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 2: Global Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 3: Global Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 4: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 5: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 6: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 7: Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 8: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 9: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 10: Global Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 11: Global Cystic Fibrosis Therapeutics Market Share Comparison by Region (2016-2032)
      • Table 12: Global Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 13: Global Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 14: North America Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 15: North America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 16: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 17: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 18: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 19: North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 20: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 21: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 22: North America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 23: North America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 24: North America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 25: North America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 26: Europe Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 27: Europe Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 28: Europe Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 29: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 30: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 31: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 32: Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 33: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 34: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 35: Europe Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 36: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 37: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 38: Europe Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 39: Asia-Pacific Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 40: Asia-Pacific Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 41: Asia-Pacific Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 42: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 43: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 44: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 45: Asia-Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 46: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 47: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 48: Asia-Pacific Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 49: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 50: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 51: Asia-Pacific Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 52: South America Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 53: South America Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 54: South America Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 55: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 56: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 57: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 58: South America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 59: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 60: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 61: South America Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 62: South America Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 63: South America Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 64: South America Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
      • Table 65: Middle East and Africa Cystic Fibrosis Therapeutics Market Comparison by Drug Class (2016-2032)
      • Table 66: Middle East and Africa Cystic Fibrosis Therapeutics Market Comparison by Route of Administration (2016-2032)
      • Table 67: Middle East and Africa Cystic Fibrosis Therapeutics Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 68: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) (2016-2032)
      • Table 69: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 70: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
      • Table 71: Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
      • Table 72: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 73: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
      • Table 74: Middle East and Africa Cystic Fibrosis Therapeutics Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
      • Table 75: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Country (2016-2032)
      • Table 76: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Drug Class (2016-2032)
      • Table 77: Middle East and Africa Cystic Fibrosis Therapeutics Market Share Comparison by Route of Administration (2016-2032)
    • AbbVie, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Vertex Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Alcresta Therapeutics, Inc.
    • Allergan
    • AstraZeneca.
    • Other Key Players
Cystic-Fibrosis Therapeutics Market
Cystic-Fibrosis Therapeutics Market
Published date: July 2024
add_shopping_cartBuy Now get_appDownload Sample

Related Reports

Cystic-Fibrosis Therapeutics Market
  • 78573
  • July 2024
    • ★★★★★
      ★★★★★
Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo

Our Clients

✖
Request a Sample Report
We'll get back to you as quickly as possible

✖
Request a Sample Report
We'll get back to you as quickly as possible

Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options